A rare inherited mutation in the Epidermal Growth Factor Receptor (EGFR) gene is associated with a 25-fold increased risk of lung cancer, according to a study by investigators at Dana-Farber Cancer Institute and 23andMe Research Institute. The findings included de-identified, aggregated genetic data from more than 3.3 million 23andMe research-consented participants.
Rare Inherited EGFR Mutation Significantly Raises Lung Cancer Risk
A study by Dana-Farber Cancer Institute and 23andMe Research Institute found a rare inherited mutation in the EGFR gene that increases lung cancer risk by 25 times. This research involved over 3.3 million participants and highlights genetic health risks that may be relevant for populations in Iran. Understanding genetic predispositions can inform public health strategies in the region.
👥 Key Players
📰 What Happened
A study revealed that a rare inherited mutation in the EGFR gene significantly increases the risk of lung cancer. This finding was based on genetic data from over 3.3 million participants.
- The mutation is associated with a 25-fold increase in lung cancer risk.
- The research utilized de-identified genetic data from a large cohort.
💡 Why It Matters
📚 Background
Lung cancer is a major health issue globally, and genetic factors can play a crucial role in individual risk assessments. The EGFR gene is known to be involved in cell growth and division, making it a key target in cancer research.
🏷️ Entities Mentioned
Translated from the original and edited for English readers. View original source →
Translation confidence: 100%